Drug Sponsors

PharmaEngine, Nanobiotix enter into Asia-Pacific exclusive license and collaboration for NBTXR3

Monday, August 6, 2012 10:27 AM

PharmaEngine, a biopharmaceutical company based in Taiwan, inked an exclusive license and collaboration agreement with France-based nanomedicine company Nanobiotix for the development and commercialization of NBTXR3.

More... »

Recordati acquires Farma-Projekt in Poland

Friday, August 3, 2012 10:48 AM

Recordati, a European pharmaceutical group based in Milan, Italy, has agreed to acquire 100% of the share capital of Farma-Projekt, a Polish pharmaceutical company, for $21.5 million.

More... »

OPKO Health acquires Farmadiet Group Holding

Friday, August 3, 2012 10:38 AM

OPKO Health, a global biopharmaceutical and diagnostics company, has decided to acquire Farmadiet Group Holding, a Spanish company that develops, manufactures and markets pharmaceutical, nutraceutical and veterinary products.

More... »

Prosetta, BMS form multi-year antiviral drug development collaboration

Wednesday, August 1, 2012 01:56 PM

Prosetta Antiviral, a San Francisco-based biotechnology company, has formed a strategic alliance with global biopharmaceutical company Bristol-Myers Squibb (BMS) to further discover and develop select drug candidates representing new, novel classes of antiviral drugs.

More... »

Dendreon to restructure operations, close N.J. plant, cut 600 positions

Wednesday, August 1, 2012 01:24 PM

Biotechnology company Dendreon has announced a strategic restructuring plan designed to accelerate the company's profitability and future growth, which includes re-configuring Dendreon's manufacturing model with the closure of its Morris Plains, N.J. manufacturing facility, restructuring administrative functions and strengthening the company's commercial functions.

More... »

Mersana raises $27M to advance Fleximer antibody-drug conjugates

Wednesday, August 1, 2012 11:34 AM

Mersana Therapeutics, a Cambridge, Mass.-based biopharmaceutical company developing Fleximer antibody-drug conjugate (ADC) platform, has closed a $27 million Series A-1 financing led by new investor New Enterprise Associates (NEA).

More... »

Anchor, Kyowa Hakko Kirin collaborate on pepducin tech for GPCR targets

Wednesday, August 1, 2012 11:15 AM

Anchor Therapeutics, a developer of pepducin technology, has entered into a collaborative agreement with Kyowa Hakko Kirin (KHK), a Japanese biopharmaceutical company, to advance KHK’s internal G protein-coupled receptor (GPCR) drug discovery portfolio.

More... »

Entries still open for U.S. Clinical Researcher of the Year 2012 competition

Wednesday, August 1, 2012 10:24 AM

There is still time to enter the U.S. Clinical Researcher of the Year competition, this year thematically focused on using resources more effectively without compromising patient safety or quality of data.

More... »

Roche, Areva Med collaborate on novel radio-immunotherapy for cancer

Monday, July 30, 2012 11:58 AM

Global biotech Roche and Areva Med, a subsidiary Areva specializing in the development of new therapies to fight cancer, have entered into a strategic collaboration to create a novel, advanced alpha radio-immunotherapy platform to target and kill cancer cells. The agreement will focus on malignant disease with a high unmet medical need.

More... »

Almirall, Quintiles sign long-term commercial U.K. partnership

Monday, July 30, 2012 10:52 AM

Global pharmaceutical company Almirall and Quintiles, a fully integrated biopharmaceutical services company, have reached a long-term strategic partnership agreement to promote Almirall’s respiratory portfolio in the U.K. commencing with a new, long-acting antimuscarinic (LAMA) delivered via an innovative, multi-dose inhaler for the treatment of chronic obstructive pulmonary disease (COPD).

More... »